Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

60 Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 41

st

Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 11:15 a.m. PST (2:15 p.m. EST) in San Francisco, CA.

A webcast of the presentation can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at

www.CaraTherapeutics.com

. An archived webcast recording will be available on the Cara website for approximately 30 days.


About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. For more information, visit

www.CaraTherapeutics.com

and follow the company on

Twitter

,

LinkedIn

and

Instagram

.


MEDIA CONTACT:


Annie Spinetta

6 Degrees

973-768-2170


[email protected]


INVESTOR CONTACT:


Iris Francesconi, Ph.D.

Cara Therapeutics

203-406-3700


[email protected]

ti?nf=ODcyMjYzOCM1MzM1OTQ2IzIwMDYwMzk= Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference


Primary Logo

Featured image: Megapixl © Maboss283

Disclaimer